US BROKER MOVES: SHEL upgraded at Morgan Stanley; PATH downgraded at Canaccord

• W. P. Carey (WPC) upgraded from Underweight to Equal Weight; PT USD 80.00 at Barclays
• Vodafone (VOD) upgraded from Sell to Buy; PT USD 20.93 (prev. USD 11.58) at Goldman Sachs
• Shell (SHEL) upgraded from Equalweight to Overweight; PT USD 101.30 (prev. USD 81.60) at Morgan Stanley
• Simmons First National (SFNC) upgraded from Neutral to Overweight; PT USD 27.50 (prev. USD 26.00) at Piper Sandler
• Planet Labs (PL) upgraded from Sell to Neutral; PT USD 22.00 at New Street Research
• Ormat Technologies (ORA) upgraded from Underperform to Market Perform; PT USD 112.00 at Bernstein SocGen Group
• Freeport-McMoRan (FCX) upgraded from Hold to Buy; PT USD 75.00 at Freedom Broker

• Vale (VALE) downgraded from N/A to Sell; PT USD 12.00 (prev. USD 14.60) at Freedom Broker
• UiPath (PATH) downgraded from Buy to Hold; PT USD 17.00 (prev. USD 15.00) at Canaccord
• Ero Copper (ERO) downgraded from Buy to Hold; PT USD 43.20 (prev. USD 40.60) at Freedom Broker
• Cal-Maine Foods (CALM) downgraded from Buy to Hold at StoneX
• Ambarella (AMBA) downgraded from Buy to Hold; PT USD 70.00 at Craig-Hallum

• Dianthus Therapeutics (DNTH) initiated Buy; PT USD 156.00 at Citi
• Belite Bio (BLTE) initiated Buy at Canaccord

Daily broker roundups of this kind rarely move the tape as a bundle; the names that travel are the ones where a rating change carries a thesis change rather than a target tweak. The standout here is the Vodafone double upgrade from Sell to Buy with a near-doubling of the target at a major house, a reversal pattern that has historically drawn more follow-through than single-notch moves because it forces fast-money positioning to cover rather than merely add. The Shell upgrade to Overweight sits within the recurring pattern of integrated oil re-ratings that cluster when houses turn on the sector's capital returns and upstream mix, and peer targets at the other majors are the usual tell for whether it is a single-analyst view or the start of a sector-wide revision cycle. The two-notch moves in small and mid caps, and the clustered downgrades in copper and protein names, tend to be stock-specific unless they spread to the peer set. On past form, initiations at biotechs with large implied upside move the underlying only where liquidity allows. The follow-on worth noting is whether any of these calls are echoed by rival desks in coming sessions, since corroboration, not the initial note, is what has historically sustained re-ratings.